Oncology

Five things for pharma marketers to know: Thursday, October 19, 2017

Five things for pharma marketers to know: Thursday, October 19, 2017

By

The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence

Five things for pharma marketers to know: Tuesday, October 17, 2017

Five things for pharma marketers to know: Tuesday, October 17, 2017

By

J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing

Nonprofits focus attention on metastatic breast cancer this October

Nonprofits focus attention on metastatic breast cancer this October

By

Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.

Five things for pharma marketers to know: Tuesday, October 10, 2017

Five things for pharma marketers to know: Tuesday, October 10, 2017

By

Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California

How a cancer nonprofit is using Comic Con in bid for new donors

How a cancer nonprofit is using Comic Con in bid for new donors

By

DKMS worked with Marino on PR for the campaign and with Area 23 on its Comic Con booth.

Five things for pharma marketers to know: Tuesday, October 3, 2017

Five things for pharma marketers to know: Tuesday, October 3, 2017

By

The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%

Five things for pharma marketers to know: Friday, September 22, 2017

Five things for pharma marketers to know: Friday, September 22, 2017

By

Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts

American Cancer Society: 'We are more than just a research organization'

American Cancer Society: 'We are more than just a research organization'

By

The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.

Five things for pharma marketers to know: Friday, September 15, 2017

Five things for pharma marketers to know: Friday, September 15, 2017

By

The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops

Five things for pharma marketers to know: Monday, September 11, 2017

Five things for pharma marketers to know: Monday, September 11, 2017

By

Teva names new CEO; Allergan transfers Restasis patent to skirt competition; Google invests in oncology

Five things for pharma marketers to know: Friday, September 1, 2017

Five things for pharma marketers to know: Friday, September 1, 2017

By

600 patients are eligible for CAR-T therapy; the FDA halts Keytruda combo study for multiple myeloma; the regulator delays decision on Herceptin biosimilar

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

By

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.

Five things for pharma marketers to know: Monday, August 21, 2017

Five things for pharma marketers to know: Monday, August 21, 2017

The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development

Top 25 oncology brands in 2016, based on U.S. sales

Top 25 oncology brands in 2016, based on U.S. sales

By

Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.

Five things for pharma marketers to know: Wednesday, August 2, 2017

Five things for pharma marketers to know: Wednesday, August 2, 2017

By

Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Friday, July 14, 2017

Five things for pharma marketers to know: Friday, July 14, 2017

By

The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika

Five things for pharma marketers to know: Thursday, July 6, 2017

Five things for pharma marketers to know: Thursday, July 6, 2017

By

The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

By

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

By

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Sunday at ASCO: What the latest trial data has to say about precision medicine

Sunday at ASCO: What the latest trial data has to say about precision medicine

By

Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

By

Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.

Why Novartis' Shah-Mehta chose a career in pharma sales

Why Novartis' Shah-Mehta chose a career in pharma sales

By

The executive director of oncology marketing is fascinated by the resilience of the human body.

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

By

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Roundtable: Social centricity in oncology

Roundtable: Social centricity in oncology

By

Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.

The immuno-oncology market prepares for the inevitable question: 'What's next?'

The immuno-oncology market prepares for the inevitable question: 'What's next?'

By

This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.

Five things for pharma marketers to know: Wednesday, May 31, 2017

Five things for pharma marketers to know: Wednesday, May 31, 2017

By

BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries

Five things for pharma marketers to know: Wednesday, May 24, 2017

Five things for pharma marketers to know: Wednesday, May 24, 2017

By

Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers

The FDA says Puma's breast-cancer drug is effective, cautions about side effects

The FDA says Puma's breast-cancer drug is effective, cautions about side effects

By

An FDA advisory committee is expected to decide Wednesday whether to recommend neratinib for approval.

Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

By

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness